<You have to give PBYI management enormous credit for designing this creative adjuvant trial >
I thought they inherited the trial design from Pfizer. Also, I thought the design was due to the tox profile of neratinib--as it was too toxic to be combined with Herceptin in an adjuvant setting.
Someone on the board knows the answer to my next question- is two years of Herceptin better than one year of Herceptin in the adjuvant setting? The only comparisons I am aware of is six months vs one year.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.